U-Neuron Biomedical

U-Neuron Biomedical Equity

The The Equity of U-Neuron Biomedical (6973.TWO) as of Oct 16, 2026 is 811.40 M TWD. In the previous year, The Equity was 491.97 M TWD — a change of 64.93% (higher).

Equity

811.40 MTWD

YoY

64.93%

Last updated:

In 2024, U-Neuron Biomedical's equity was 811.40 M TWD, a 64.93% increase from the 491.97 M TWD equity in the previous year.

The U-Neuron Biomedical Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2021
195.44 M TWD
Jan 1, 2022
163.27 M TWD
Jan 1, 2023
491.97 M TWD
Jan 1, 2024
811.40 M TWD
The U-Neuron Biomedical Equity history
YEAREquityYoY
811.40 MTWD+64.93%
491.97 MTWD+201.33%
163.27 MTWD-16.46%
195.44 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

U-Neuron Biomedical Stock analysis

What does U-Neuron Biomedical do? U-Neuron Biomedical Inc, headquartered in Taipei, Taiwan, operates in the Health Care sector within the Biotechnology industry. The company, listed on 20 July 2023, develops cosmetics, health care consumer products, and new drugs. Its drug development focuses on allogeneic amniotic fluid stem cells for applications like erectile dysfunction (UA002) and dry eye (UB003). Cosmetic products, featuring deer amniotic fluid stem cell derivatives, include anti-aging masks, essences, and creams for repair and hydration, primarily sold domestically in Taiwan. U-Neuron Biomedical is one of the most popular companies on Eulerpool.

Equity Details

Analyzing U-Neuron Biomedical's Equity

U-Neuron Biomedical's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding U-Neuron Biomedical's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating U-Neuron Biomedical's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

U-Neuron Biomedical's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in U-Neuron Biomedical’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about U-Neuron Biomedical stock

The Equity of U-Neuron Biomedical is 811.40 M TWD in 2024.

The Equity of U-Neuron Biomedical changed from 491.97 M TWD to 811.40 M TWD, representing a 64.93% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity U-Neuron Biomedical since 2006 – with annual values, charts, and detailed analysis.

The Equity's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's U-Neuron Biomedical historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — U-Neuron Biomedical

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — U-Neuron Biomedical